Cencora, Inc. $COR Shares Sold by Prudential PLC

Prudential PLC trimmed its position in Cencora, Inc. (NYSE:COR) by 44.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,539 shares of the company’s stock after selling 10,093 shares during the period. Prudential PLC’s holdings in Cencora were worth $4,235,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Oakworth Capital Inc. acquired a new stake in Cencora in the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC acquired a new stake in Cencora in the fourth quarter valued at approximately $27,000. Archer Investment Corp boosted its stake in Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after acquiring an additional 47 shares in the last quarter. Optima Capital LLC acquired a new stake in Cencora in the fourth quarter valued at approximately $31,000. Finally, Basepoint Wealth LLC acquired a new stake in Cencora in the fourth quarter valued at approximately $32,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Trading Up 1.7%

Shares of Cencora stock opened at $274.94 on Friday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The firm has a fifty day moving average price of $292.70 and a 200 day moving average price of $330.55. Cencora, Inc. has a 1 year low of $244.82 and a 1 year high of $377.54. The stock has a market cap of $53.49 billion, a PE ratio of 21.08, a price-to-earnings-growth ratio of 1.48 and a beta of 0.59.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion for the quarter, compared to analysts’ expectations of $81.09 billion. During the same period last year, the business earned $4.42 EPS. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts predict that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora announced that its board has initiated a stock repurchase program on Thursday, May 21st that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is 18.40%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on COR. William Blair began coverage on shares of Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating for the company. Robert W. Baird decreased their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Weiss Ratings cut shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Finally, Evercore set a $360.00 price target on shares of Cencora in a report on Wednesday, April 8th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.